High ApoB, CAC Zero: What Your Heart Tests Are Really Saying

High ApoB but clean metabolic labs. CAC zero but inherited Lp(a). A normal stress test but plaque on CCTA. This is where heart-disease prevention gets noi…

Published July 10, 20261:10:40The Longevity Show

Two confident, well-read people are arguing online. One says drive ApoB as low as humanly possible. The other says that if your insulin, triglycerides and blood pressure are good, your lipid panel is beside the point. Dr. Lin's argument is that this is not a disagreement about science — it is two people each holding one piece of the same puzzle.

The episode replaces the metaphor that causes most of the confusion. Your artery is not a pipe that grease clogs. It is a road inside a living city: traffic is your ApoB-containing particles, cargo is the cholesterol they carry, force is blood pressure, road conditions are metabolic health, genes are intelligence reports, imaging is a set of surveillance cameras each pointed at a different street, and the disaster the whole city is organised around preventing is a clot.

Once the pieces are separated, the apparent contradictions dissolve — including the one in the title. A high ApoB with a calcium score of zero is not a paradox. It is two cameras answering two different questions, and the mistake is reading them as though they answered the same one.

Before you watch

The disease starts in the artery wall, not in the channel. Particles cross the endothelium, get caught by proteoglycans like burrs in carpet, oxidise, and summon immune cells that become foam cells. The body then paves over the mess with a fibrous cap and later calcium. A heart attack is the moment that repair scar ruptures — which is why roughly half of heart attacks happen in people with a normal lipid panel.
ApoB counts vehicles; LDL-C counts cargo. Same cargo can ride in a few loaded trucks or a swarm of half-empty motorbikes, and the wall gets hit by particles one at a time. When the two disagree, ApoB wins — a 2025 review found it beat LDL-C in all nine discordance comparisons and non-HDL-C in seven of nine.
Exposure is causal and cumulative, which is the piece both sides of the argument drop. A 2017 European Atherosclerosis Society consensus drawing on more than two million people found the damage is height multiplied by duration. Think ApoB-years the way we think pack-years: high ApoB for six months at 32 is a different thing from thirty years of it at 62.
Metabolic perfection does not cancel particle burden. Excellent insulin sensitivity is a road-conditions win and genuinely lowers concern — but it does not make the traffic disappear. Both levers are worth pulling, and neither is a substitute for the other.
On the lean mass hyper-responder question, Dr. Lin engages rather than dismisses. The 2024 study people cite is a cross-sectional CCTA snapshot of a selected group after about 4.7 years — imaging, not events, with no randomisation and no information about the pace of progression. And the longitudinal paper often quoted as 'plaque predicts plaque, ApoB does not' was retracted this year for methodological problems.
Lp(a) is not just LDL in a costume. Per particle, a 2024 genetic analysis estimated it at roughly six times more atherogenic than LDL for coronary heart disease — it carries oxidised phospholipids and an apo(a) tail that chemically resembles plasminogen, tying it to clotting biology. Treat that figure as population genetics rather than a personal risk calculator.
A calcium score of zero alongside a high Lp(a) is not permission to relax. CAC only reports calcified plaque today; Lp(a) is inherited lifetime risk. A 2022 analysis found each predicts events independently and people carrying both are at highest risk — while a 2026 multi-cohort study of over 11,000 people followed 15 years found CAC still stratifies risk even when Lp(a) is high. Defer to the higher-risk item and squeeze every modifiable factor harder.
Serial calcium scoring is the wrong scoreboard. Calcified plaque does not melt away, and CAC often rises on effective treatment because statins stabilise soft plaque by calcifying it. A rising score in someone newly treated is more likely good news than bad. If you want to see whether plaque is regressing, CCTA is the camera — GLAGOV showed plaque volume shrinking, and PACMAN-AMI showed plaques becoming smaller and more stable with thicker caps after adding a PCSK9 inhibitor.
A biomarker moving, an image improving, and events falling are three separate proof points, and clearing one does not clear the next. A drug targeting apoC3 drove triglycerides and remnant cholesterol sharply down without significantly reducing non-calcified plaque volume over 12 months. Niacin lowers Lp(a) modestly and failed to reduce events in AIM-HIGH and HPS2-THRIVE. And CIRT showed that low-dose methotrexate did nothing, even though CANTOS proved inflammation matters — the biology has to match the pathway.
Use a four-step test on any supplement: plausible mechanism, biomarker change, imaging change, outcome change. Almost everything sold is stuck at step one. Nattokinase showed no meaningful effect on carotid measures over three years; vitamin K2 data is mixed; berberine moves labs without outcome proof. Red yeast rice deserves particular care — its active compound is chemically a statin, so you get statin interactions with supplement-grade dosing consistency.
Blood pressure gets far less internet attention than it deserves. SPRINT randomised over 9,000 higher-risk adults to a systolic target below 120 versus 140 and cut major cardiovascular events by about 25% and all-cause mortality by 27% — though with more adverse events, so frailty and falls matter in who this suits.

Chapters

Questions

My ApoB is high but my calcium score is zero. Which do I believe?

Both, because they answer different questions. CAC tells you whether calcified plaque exists today; it is blind to soft plaque and says nothing about the next thirty years. ApoB tells you the ongoing exposure that determines whether plaque forms. A zero score at 25 does not mean what a zero score at 65 means. Dr. Lin's own case is exactly this — ApoB of 128 with a CAC of zero — and her read was that she had caught it early rather than that she was exempt.

If my metabolic health is perfect, does my ApoB still matter?

Yes, though less than it would otherwise. Great metabolic health means good road conditions, which genuinely lowers the chance that any given particle causes trouble. But it does not remove the traffic. The honest framing is that you are lowering the probability of an accident rather than eliminating the exposure — and since the damage accumulates over decades, betting on staying metabolically perfect for the rest of your life is a large bet. Life intervenes: illness, inflammation, ageing.

Can plaque actually be reversed?

Partly, and it depends what you mean. Calcified plaque is scar tissue and does not melt away — the goal there is stability. Soft, lipid-rich plaque can shrink and stabilise, and the strongest evidence is intensive ApoB lowering with statins, ezetimibe and PCSK9 inhibitors. GLAGOV and PACMAN-AMI both showed measurable improvement. But remember the real prize is not a better-looking scan; it is not having the heart attack.

I'm worried about statin side effects. How should I think about them?

Take the symptoms seriously and the attribution sceptically. SAMSON blinded people who had quit statins through statin, placebo and no-pill months — symptoms were much higher in both statin and placebo months than no-pill months, and the statin and placebo months looked nearly identical. The symptoms are real; the molecule may not be the whole cause. Serious muscle injury runs under 0.1% and serious liver toxicity around 0.001%. The diabetes signal is real, dose-related, and concentrated in people already near the threshold. There are many outs: lower dose, different statin, alternate-day dosing, or a lower dose combined with ezetimibe, a PCSK9 inhibitor or bempedoic acid.

Can you drive cholesterol too low?

It is a fair biological question, and the trial data is reassuring. Your brain manufactures and manages its own cholesterol behind the blood-brain barrier, so lowering blood levels does not starve it. FOURIER-OLE found LDL-C below 20 associated with lower cardiovascular risk and no significant safety signal across haemorrhagic stroke, neurocognitive events, diabetes, cataracts, cancer or non-cardiovascular death, and the EBBINGHAUS follow-up found no cognitive signal at a median LDL-C around 35. For high-risk patients the question becomes how low you can get safely and sustainably.

I have an ApoE4 allele. How worried should I be?

Informed rather than worried. Roughly one in four people carry a single E4 copy. A 2007 JAMA meta-analysis found about 20% higher coronary risk with one copy and 40–45% with two, compared to the common E3/E3 — real, but a long way from destiny. Dr. Lin treats it as intelligence: a reason to look earlier and harder at ApoB, triglycerides, insulin resistance and blood pressure, and to intervene sooner. She also argues family history is often more informative than the genotype, because it reflects how the genes actually played out in real lives.

The Longevity Letter